Business News

Genfit Discontinues Phase 3 Trial of Elafibranor in NASH After Failing Interim Analysis

Lille (France), Cambridge (Massachusetts, United States), July 22, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the discontinuation of the RESOLVE-IT Phase 3 clinical trial of elafibranor in adults with non-alcoholic steatohepatitis (NASH) and …

Read More »

Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan in Lung and Breast Cancer

TOKYO & BASKING RIDGE, N.J. & MUNICH & VILLEJUIF, France–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Gustave Roussy today announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and patritumab deruxtecan (U3-1402), two of Daiichi Sankyo’s lead DXd antibody drug conjugates (ADCs), …

Read More »

Gilead Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc., a privately held company developing first-in-class cancer immunotherapies. Gilead will also receive an exclusive option to acquire the …

Read More »

Jnana Therapeutics and Roche Collaborate to Discover Novel Medicines to Treat Immune-Mediated and Neurological Diseases

BOSTON–(BUSINESS WIRE)–Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of small molecule drugs directed at the solute carrier (SLC) family of metabolite transporters as a broad, innovative approach for modulating cellular metabolism to treat immune-mediated and neurological diseases. …

Read More »

GSK and CureVac Announce Strategic mRNA Technology Collaboration

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac today announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialization of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. mRNA (messenger …

Read More »

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have …

Read More »

Thermo Fisher Increases Takeover Price for COVID-19 Testing Supplier Qiagen by $1 Billion

WALTHAM, Mass. and VENLO, The Netherlands, July 16, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of Sample to Insight molecular diagnostics and sample preparation technologies, today announced that they …

Read More »

Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead’s SYK Inhibitor Portfolio

SAN MATEO, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced that it has entered into an asset purchase agreement with Gilead Sciences, Inc. to acquire Gilead’s …

Read More »

Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with Keytruda in NSCLC

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields together with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatment of non-small cell lung cancer (NSCLC). Novocure’s …

Read More »

Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK

BOSTON and LONDON, July 15, 2020 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has entered into two worldwide royalty-bearing license agreements with GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) for use of their proprietary lentiviral stable cell line technology (LV-SCLT) for Orchard’s …

Read More »